China's National Medical Products Administration accepted the application of Beijing Centergate Technologies Holding's (SHE:000931) subsidiary, Beijing Huasu Pharmaceutical, to market extended-release oxycodone hydrochloride tablets, according to a Shenzhen Stock Exchange disclosure on Thursday.
The drug is used for the treatment of severe pain that requires long-term, continuous use of opioids, and when substitution therapies are not adequate to relieve the pain, the Chinese biomedicine and healthcare company said.
The company's shares closed 2% higher.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。